Nearly 12% of patients who were identified as having experienced a serious opioid-induced respiratory depression event had documented nasal obstruction pathology, according to a retrospective analysis of a large insurance database that was presented at PAINWeek 2016.
“This is a fairly high percentage,” said lead investigator Scott G. Weiner, MD, MPH, attending emergency physician at Brigham and Women’s Hospital, in Boston, as well as director of the hospital- and community-wide